Metal pollutants and cardiovascular disease: Mechanisms and consequences of exposure

American Heart Journal

Volumn 168, Issue 6, 2014, Pages 812-822

  Solenkova, Natalia V ^a   Newman, Jonathan D ^b   Berger, Jeffrey S ^b   Thurston, George ^b   Hochman, Judith S ^b   Lamas, Gervasio A ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC; C REACTIVE PROTEIN; CADMIUM; CREATININE; CYSTEINE; EDETIC ACID; FIBRINOGEN; GLUTATHIONE; HIGH DENSITY LIPOPROTEIN; HOMOCYSTEINE; LEAD; LOW DENSITY LIPOPROTEIN; MERCURY; METALLOTHIONEIN; THIOL GROUP; THIOMERSAL; XENOBIOTIC AGENT; METAL; POLLUTANT;

ABSORPTION; ARTICLE; ATHEROSCLEROSIS; BLACKFOOT DISEASE; BODY DISTRIBUTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CELL PROLIFERATION; CHELATION THERAPY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENDOTHELIUM CELL; ENVIRONMENTAL EXPOSURE; EXCRETION; HEART INFARCTION; HUMAN; HYPERTENSION; LEAD BLOOD LEVEL; MACROPHAGE; OXIDATIVE STRESS; PERIPHERAL OCCLUSIVE ARTERY DISEASE; POLLUTANT; SYSTOLIC BLOOD PRESSURE; URINE LEVEL; ADVERSE EFFECTS; ANALYSIS; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); PROCEDURES; RISK FACTOR;

ARSENIC; CADMIUM; CARDIOVASCULAR DISEASES; CHELATION THERAPY; CLINICAL TRIALS AS TOPIC; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL POLLUTANTS; HUMANS; LEAD; MERCURY; METALS; RISK FACTORS; XENOBIOTICS;

EID: 84912125409     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.07.007     Document Type: Review

References (100)

1. Agency for Toxic Substances and Disease Registry (ATSDR). The priority list of hazardous substances. Atlanta (GA): U.S. Department of Health and Human Services, Public Health Service; 2011.
2. Abadin H, Ashizawa A, Stevens YW, et al. Agency for Toxic Substances and Disease Registry (ATSDR) Toxicological Profiles. Toxicological Profile for Lead. Atlanta (GA): U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES. 2007.
3. Skerfving S, Bergdahl IA. Lead. In: Nordberg GF, Fowler BA, Nordberg M, Friberg LT, eds. Handbook on the toxicology of metals. 3rd ed. Elsevier; 2007. p. 599-643.
4. Chisolm Jr JJ, Harrison HE. The exposure of children to lead. Pediatrics 1956;18(6):943-58.
5. Papanikolaou NC, Hatzidaki EG, Belivanis S, et al. Lead toxicity update. A brief review. Med Sci Monit 2005;11(10):RA329-36.
6. Kessler R. Sunset for leaded aviation gasoline? Environ Health Perspect 2013;121(2):a54-7.
7. Ahlgren L, Liden K, Mattsson S, et al. X-ray fluorescence analysis of lead in human skeleton in vivo. Scand J Work Environ Health 1976;2(2):82-6.
8. Rosen JF, Markowitz ME, Bijur PE, et al. L-line x-ray fluorescence of cortical bone lead compared with the CaNa2EDTA test in lead-toxic children: public health implications. Proc Natl Acad Sci U S A 1989;86(2):685-9.
9. Kosnett MJ, Wedeen RP, Rothenberg SJ, et al. Recommendations for medical management of adult lead exposure. Environ Health Perspect 2007;115(3):463-71.
10. Menke A, Muntner P, Batuman V, et al. Blood lead below 0.48 micromol/L (10 microg/dL) and mortality among US adults. Circulation 2006;114(13):1388-94.
11. Navas-Acien A, Selvin E, Sharrett AR, et al. Lead, cadmium, smoking, and increased risk of peripheral arterial disease. Circulation 2004;109(25):3196-201.
12. Nash D, Magder L, Lustberg M, et al. Blood lead, blood pressure, and hypertension in perimenopausal and postmenopausal women. JAMA 2003;289(12):1523-32.
13. Weisskopf MG, Jain N, Nie H, et al. A prospective study of bone lead concentration and death from all causes, cardiovascular diseases, and cancer in the Department of Veterans Affairs Normative Aging Study. Circulation 2009;120(12):1056-64.
14. Lustberg M, Silbergeld E. Blood lead levels and mortality. Arch Intern Med 2002;162(21):2443-9.
15. Pirkle JL, Schwartz J, Landis JR, et al. The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. Am J Epidemiol 1985;121(2):246-58.
16. Harlan WR, Landis JR, Schmouder RL, et al. Blood lead and blood pressure. Relationship in the adolescent and adult US population. JAMA 1985;253(4):530-4.
17. Nawrot TS, Thijs L, Den Hond EM, et al. An epidemiological reappraisal of the association between blood pressure and blood lead: a meta-analysis. J Hum Hypertens 2002;16(2):123-31.
18. Stohs SJ, Bagchi D. Oxidative mechanisms in the toxicity of metal ions. Free Radic Biol Med 1995;18(2):321-36.
19. Revis NW, Zinsmeister AR, Bull R. Atherosclerosis and hypertension induction by lead and cadmium ions: an effect prevented by calcium ion. Proc Natl Acad Sci U S A 1981;78(10):6494-8.
20. Aalbers TG, Houtman JP. Relationships between trace elements and atherosclerosis. Sci Total Environ 1985;43(3):255-83.
21. Voors AW, Shuman MS, Johnson WD. Additive statistical effects of cadmium and lead on heart-related disease in a North Carolina autopsy series. Arch Environ Health 1982;37(2):98-102.
22. Li WF, Pan MH, Chung MC, et al. Lead exposure is associated with decreased serum paraoxonase 1 (PON1) activity and genotypes. Environ Health Perspect 2006;114(8):1233-6.
23. Peters JL, Kubzansky LD, Ikeda A, et al. Lead concentrations in relation to multiple biomarkers of cardiovascular disease: the Normative Aging Study. Environ Health Perspect 2012;120(3):361-6.
24. Skoczynska A, Smolik R, Jelen M. Lipid abnormalities in rats given small doses of lead. Arch Toxicol 1993;67(3):200-4.
25. Nordberg GF, Nogawa K, Nordberg M, et al. Cadmium. In: Nordberg GF, Fowler BA, Nordberg M, Friberg LT, eds. Handbook on the toxicology of metals. 3rd ed. Elsevier; 2007. p. 445-86.
26. Wagner GJ, Yeargan R. Variation in cadmium accumulation potential and tissue distribution of cadmium in tobacco. Plant Physiol 1986;82(1):274-9.
27. Jarup L, Berglund M, Elinder CG, et al. Health effects of cadmium exposure - a review of the literature and a risk estimate. Scand J Work Environ Health 1998;24(Suppl 1):1-51.
28. Menke A, Muntner P, Silbergeld EK, et al. Cadmium levels in urine and mortality among U.S. adults. Environ Health Perspect 2009;117(2):190-6.
29. Nawrot TS, Staessen JA, Roels HA, et al. Cadmium exposure in the population: from health risks to strategies of prevention. Biometals 2010;23(5):769-82.
30. Horiguchi H, Oguma E, Sasaki S, et al. Comprehensive study of the effects of age, iron deficiency, diabetes mellitus, and cadmium burden on dietary cadmium absorption in cadmium-exposed female Japanese farmers. Toxicol Appl Pharmacol 2004;196(1):114-23.
31. Berglund M, Akesson A, Nermell B, et al. Intestinal absorption of dietary cadmium in women depends on body iron stores and fiber intake. Environ Health Perspect 1994;102(12):1058-66.
32. National Report on Human Exposure to Environmental Chemicals. CDC; 2009.
33. Tellez-Plaza M, Navas-Acien A, Menke A, et al. Cadmium exposure and all-cause and cardiovascular mortality in the U.S. general population. Environ Health Perspect 2012;120(7):1017-22.
34. Tellez-Plaza M, Guallar E, Howard BV, et al. Cadmium exposure and incident cardiovascular disease. Epidemiology 2013;24(3):421-9.
35. Tellez-Plaza M, Jones MR, Dominguez-Lucas A, et al. Cadmium exposure and clinical cardiovascular disease: a systematic review. Curr Atheroscler Rep 2013;15(10):356-71.
36. Tellez-Plaza M, Navas-Acien A, Crainiceanu CM, et al. Cadmium and peripheral arterial disease: gender differences in the 1999-2004 US National Health and Nutrition Examination Survey. Am J Epidemiol 2010;172(6):671-81.
37. Navas-Acien A, Silbergeld EK, Sharrett R, et al. Metals in urine and peripheral arterial disease. Environ Health Perspect 2005;113(2):164-9.
38. Tellez-Plaza M, Navas-Acien A, Crainiceanu CM, et al. Cadmium exposure and hypertension in the 1999-2004 National Health and Nutrition Examination Survey (NHANES). Environ Health Perspect 2008;116(1):51-6.
39. Berlin M, Zalups RK, Fowler BA. Mercury. In: Nordberg GF, Fowler BA, Nordberg M, Friberg LT, eds. Handbook on the toxicology of metals. 3rd ed. Elsevier; 2007. p. 675-729.
40. Mercury in canned tuna still a concern: new tests reinforce a need for some people to limit consumption. Consum Rep 2011;76(1):20-1.
41. Agency for Toxic Substances and Disease Registry (ATSDR) Toxicological Profiles. Toxicological profile for mercur. Atlanta (GA): U.S. Department of Health and Human Services, Public Health Service. 1999.
42. Ganther HE. Modification of methylmercury toxicity and metabolism by selenium and vitamin E: possible mechanisms. Environ Health Perspect 1978;25:71-6.
43. Mozaffarian D. Fish, mercury, selenium and cardiovascular risk: current evidence and unanswered questions. Int J Environ Res Public Health 2009;6(6):1894-916.
44. Mozaffarian D, Shi P, Morris JS, et al. Mercury exposure and risk of cardiovascular disease in two U.S. cohorts. N Engl J Med 2011;364 (12):1116-25.
45. WHO (World Health Organization). Elemental mercury and inorganic mercury compounds: human health aspects. Concise International Chemical Assessment Document 50. Geneva, Switzerland: WHO. 2003.
46. WHO (World Health Organization). Environmental Health Criteria 101, Methylmercury. Geneva, Switzerland: WHO. 1990.
47. Occupational Safety and Health Standards. Mercury. US Department of Labor, Occupational Safety and Health Administration (OSHA). 2007.
48. Salonen JT, Seppanen K, Nyyssonen K, et al. Intake of mercury from fish, lipid peroxidation, and the risk of myocardial infarction and coronary, cardiovascular, and any death in eastern Finnish men. Circulation 1995;91(3):645-55.
49. Guallar E, Sanz-Gallardo MI, van't Veer P, et al. Mercury, fish oils, and the risk of myocardial infarction. N Engl J Med 2002;347(22):1747-54.
50. Salonen JT, Seppanen K, Lakka TA, et al. Mercury accumulation and accelerated progression of carotid atherosclerosis: a population-based prospective 4-year follow-up study in men in eastern Finland. Atherosclerosis 2000;148(2):265-73.
51. Valera B, Dewailly E, Poirier P. Environmental mercury exposure and blood pressure among Nunavik Inuit adults. Hypertension 2009;54(5):981-6.
52. Vupputuri S, Batuman V, Muntner P, et al. Effect of blood pressure on early decline in kidney function among hypertensive men. Hypertension 2003;42(6):1144-9.
53. Pedersen EB, Jorgensen ME, Pedersen MB, et al. Relationship between mercury in blood and 24-h ambulatory blood pressure in Greenlanders and Danes. Am J Hypertens 2005;18(5 Pt 1):612-8.
54. Kobal AB, Horvat M, Prezelj M, et al. The impact of long-term past exposure to elemental mercury on antioxidative capacity and lipid peroxidation in mercury miners. J Trace Elem Med Biol 2004;17(4):261-74.
55. Fowler BA, Selene CH, Chou J, et al. Arsenic. In: Nordberg GF, Fowler BA, Nordberg M, Friberg LT, eds. Handbook on the toxicology of metals. 3rd ed. Elsevier; 2007. p. 367-406.
56. WHO (World Health Organization). Environmental Health Criteria 18, Arsenic. Geneva, Switzerland: WHO. 1981.
57. Smith AH, Lopipero PA, Bates MN, et al. Public health. Arsenic epidemiology and drinking water standards. Science 2002;296 (5576):2145-6.
58. Tellez-Plaza M, Gribble MO, Voruganti VS, et al. Heritability and preliminary genome-wide linkage analysis of arsenic metabolites in urine. Environ Health Perspect 2013;121(3):345-51.
59. Chen Y, Wu F, Liu M, et al. A prospective study of arsenic exposure, arsenic methylation capacity, and risk of cardiovascular disease in Bangladesh. Environ Health Perspect 2013;121(7):832-8.
60. Agency for Toxic Substances and Disease Registry (ATSDR) Toxicological Profiles. Toxicological profile for arsenic. Atlanta (GA): U.S. Department of Health and Human Services, Public Health Service. 2007.
61. American Conference of Government Industrial Hygienists (ACGIH). Documentation of biological exposure indicesCincinnati (OH): ACGIH Worldwide; 2001.
62. Moon KA, Guallar E, Umans JG, et al. Association between exposure to low to moderate arsenic levels and incident cardiovascular disease: a prospective cohort study. Ann Intern Med 2013;159(10):649-59.
63. Chen Y, Graziano JH, Parvez F, et al. Arsenic exposure from drinking water and mortality from cardiovascular disease in Bangladesh: prospective cohort study. Br Med J 2011;342:d2431, http://dx.doi.org/10.1136/bmj.d2431.
64. Engel RR, Smith AH. Arsenic in drinking water and mortality from vascular disease: an ecologic analysis in 30 counties in the United States. Arch Environ Health 1994;49(5):418-27.
65. Tseng CH, Chong CK, Chen CJ, et al. Dose - response relationship between peripheral vascular disease and ingested inorganic arsenic among residents in blackfoot disease endemic villages in Taiwan. Atherosclerosis 1996;120(1-2):125-33.
66. Abhyankar LN, Jones MR, Guallar E, et al. Arsenic exposure and hypertension: a systematic review. Environ Health Perspect 2012;120(4):494-500.
67. Gilbert HF. Thiol/disulfide exchange equilibria and disulfide bond stability. Methods Enzymol 1995;251:8-28.
68. Leonarduzzi G, Gamba P, Gargiulo S, et al. Inflammation-related gene expression by lipid oxidation-derived products in the progression of atherosclerosis. Free Radic Biol Med 2012;52(1):19-34.
69. Valko M, Morris H, Cronin MT. Metals, toxicity and oxidative stress. Curr Med Chem 2005;12(10):1161-208.
70. Yiin SJ, Lin TH. Lead-catalyzed peroxidation of essential unsaturated fatty acid. Biol Trace Elem Res 1995;50(2):167-72.
71. Yucebilgic G, Bilgin R, Tamer L, et al. Effects of lead on Na(+)-K(+) ATPase and Ca(+2) ATPase activities and lipid peroxidation in blood of workers. Int J Toxicol 2003;22(2):95-7.
72. Vaziri ND, Ding Y, Ni Z. Nitric oxide synthase expression in the course of lead-induced hypertension. Hypertension 1999;34(4 Pt 1):558-62.
73. Vaziri ND, Ding Y. Effect of lead on nitric oxide synthase expression in coronary endothelial cells: role of superoxide. Hypertension 2001;37(2):223-6.
74. Eckhardt W, Bellmann K, Kolb H. Regulation of inducible nitric oxide synthase expression in beta cells by environmental factors: heavy metals. Biochem J 1999;338(Pt 3):695-700.
75. Demontis MP, Varoni MV, Volpe AR, et al. Role of nitric oxide synthase inhibition in the acute hypertensive response to intracerebroventricular cadmium. Br J Pharmacol 1998;123(1):129-35.
76. Bhatnagar A. Environmental cardiology: studying mechanistic links between pollution and heart disease. Circ Res 2006;99(7):692-705.
77. Zhao Y, Wang L, Shen HB, et al. Association between delta-aminolevulinic acid dehydratase (ALAD) polymorphism and blood lead levels: a meta-regression analysis. J Toxic Environ Health A 2007;70(23):1986-94.
78. Flora SJ, Flora G, Saxena G, et al. Arsenic and lead induced free radical generation and their reversibility following chelation. Cell Mol Biol 2007;53(1):26-47.
79. Carmignani M, Boscolo P, Poma A, et al. Kininergic system and arterial hypertension following chronic exposure to inorganic lead. Immunopharmacology 1999;44(1-2):105-10.
80. Vander AJ. Chronic effects of lead on the renin-angiotensin system. Environ Health Perspect 1988;78:77-83.
81. Bergquist ER, Fischer RJ, Sugden KD, et al. Inhibition by methylated organo-arsenicals of the respiratory 2-oxo-acid dehydrogenases. J Organomet Chem 2009;694(6):973-80.
82. Wu F, Jasmine F, Kibriya MG, et al. Association between arsenic exposure from drinking water and plasma levels of cardiovascular markers. Am J Epidemiol 2012;175(12):1252-61.
83. Tseng CH. The potential biological mechanisms of arsenic-induced diabetes mellitus. Toxicol Appl Pharmacol 2004;197(2):67-83.
84. Messner B, Knoflach M, Seubert A, et al. Cadmium is a novel and independent risk factor for early atherosclerosis mechanisms and in vivo relevance. Arterioscler Thromb Vasc Biol 2009;29(9):1392-8.
85. Lin YS, Rathod D, HoWC, et al. Cadmium exposure is associated with elevated blood C-reactive protein and fibrinogen in the U. S. population: the third national health and nutrition examination survey (NHANES III, 1988-1994). Ann Epidemiol 2009;19(8):592-6.
86. Jiang SJ, Lin TM, Wu HL, et al. Decrease of fibrinolytic activity in human endothelial cells by arsenite. Thromb Res 2002;105(1):55-62.
87. Knoflach M, Messner B, Shen YH, et al. Non-toxic cadmium concentrations induce vascular inflammation and promote atherosclerosis. Circ J 2011;75(10):2491-5.
88. Manigrasso MB, Juranek J, Ramasamy R, et al. Unlocking the biology of RAGE in diabetic microvascular complications. Trends in endocrinology and metabolism. TEM. 2013.
89. Nagai R, Murray DB, Metz TO, et al. Chelation: a fundamental mechanism of action of AGE inhibitors, AGE breakers, and other inhibitors of diabetes complications. Diabetes 2012;61(3):549-59.
90. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40(4):405-12.
91. Monnier VM. Transition metals redox: reviving an old plot for diabetic vascular disease. J Clin Invest 2001;107(7):799-801.
92. Agarwal S, Zaman T, Tuzcu EM, et al. Heavy metals and cardiovascular disease: results from the National Health and Nutrition Examination Survey (NHANES) 1999-2006. Angiology 2011;62(5):422-9.
93. Clarke CN, Clarke NE, Mosher RE. Treatment of angina pectoris with disodium ethylene diamine tetraacetic acid. Am J Med Sci 1956;232(6):654-66.
94. Dans AL, Tan FN, Villarruz-Sulit EC. Chelation therapy for atherosclerotic cardiovascular disease. Cochrane Database of Systematic Reviews 2002;4:1-31, http://dx.doi.org/10.1002/14651858.CD002785.CD002785.
95. Lamas GA, Goertz C, Boineau R, et al. Design of the Trial to Assess Chelation Therapy (TACT). Am Heart J 2012;163(1):7-12.
96. Lamas GA, Goertz C, Boineau R, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA 2013;309(12):1241-50.
97. Escolar E, Lamas GA, Mark DB, et al. The Effect of an EDTA-based Chelation Regimen on Patients With Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT). Circ Cardiovasc Qual Outcomes 2014;7:15-24.
98. Salonen JT, Seppänen K, Nyyssönen K, et al. Mercury, fish oils, and risk of acute coronary events and cardiovascular disease, coronary heart disease, and all-cause mortality in men in Eastern Finland. Arterioscler Thromb Vasc Biol 2004;91:645-55. [Internet, Available from:, http://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=7828289&retmode=ref&cmd=prlinks].
99. Yoshizawa K, Rimm EB, Morris JS, et al. Mercury and the risk of coronary heart disease in men. N Engl J Med 2002;347:1755-60.
100. Nakagawa H, Nishijo M, Morikawa Y, et al. Urinary cadmium and mortality among inhabitants of a cadmium-polluted area in Japan. Environ Res 2006;100:323-9.